Clinical trials: Anxiety, Generalized
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Generalized Anxiety Disorder
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00730691
- Testing
- Vortioxetine, Duloxetine
- Where
- 66 sites in United States
- Volunteers
- 781 people
- Sponsor
- Takeda
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd
Anxiety Disorders
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum.
- Trial name
- NCT00612859
- Testing
- levetiracetam
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Anxiety Disorders
A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)
This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in adults with GAD. Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who fulfill the inclusion/exclusion…
- Trial name
- NCT00248183
- Testing
- PRX-00023
- Where
- 20 sites in United States
- Volunteers
- 310 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Generalized Anxiety Disorder
A Study of Duloxetine in Elderly Generalized Anxiety Disorder
The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD).
- Trial name
- NCT01118780
- Testing
- Duloxetine
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
Generalized Anxiety Therapy Effectiveness
This study will examine the effectiveness of digital CBT versus psychoeducation in improving anxiety for those with Generalized Anxiety Disorder.
- Trial name
- GATE (NCT05748652)
- Testing
- digital CBT, Psychoeducation
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Big Health Inc.
Depression - Major Depressive Disorder, Anxiety
Singula Phase 0.1 Primary Care Pilot
This prospective, single-arm, observational pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care.
- Trial name
- NCT07834684
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Singula Health, Inc.
Generalized Anxiety Disorder
POC Study in Partially Responsive Generalized Anxiety Disorder
This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel…
- Trial name
- NCT02310568
- Testing
- PF-06372865.
- Where
- 47 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Anxiety
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
The purpose of the study is to compare pregabalin to Venlafaxine XR and placebo in the treatment of generalized anxiety disorder.
- Trial name
- NCT00151450
- Testing
- Pregabalin, Venlafaxine XR
- Where
- 45 sites in Belgium, Canada and 6 more
- Volunteers
- 390 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anxiety Disorder Generalized
А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding pilot study to assess the efficacy and safety of CD-008-0045 in patients with Generalized Anxiety Disorder (GAD).
- Trial name
- NCT04524975
- Testing
- CD-008-0045
- Where
- 15 sites in Russia
- Volunteers
- 129 people
- Sponsor
- ChemRar Research and Development Institute, LLC
Generalized Anxiety Disorder
Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function
This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.
- Trial name
- NCT07457190
- Testing
- Buagafuran
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Generalized Anxiety Disorder
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
- Trial name
- NCT03829241
- Testing
- Troriluzole
- Where
- 53 sites in United States
- Volunteers
- 881 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Anxiety Disorders
Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder
The purpose of the study is to evaluate the efficacy and safety of SR58611A (350 mg BID) compared to placebo in the prevention of relapse of anxiety, in patients with Generalized Anxiety Disorder improved after 12 weeks of…
- Trial name
- VEGA (NCT00397098)
- Testing
- SR58611A
- Where
- 9 sites in Australia, Chile and 7 more
- Volunteers
- 257 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
The purpose of this study is to investigate the absorption, metabolism and excretion of [14C] PD 0332334 to characterize plasma, fecal and urinary radioactivity and identify any metabolites of [14C] PD 0332334.
- Trial name
- NCT00537615
- Testing
- PD 0332334
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Social Phobia, Social Anxiety Disorder
Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia
The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.
- Trial name
- PH94B-SAD (NCT01217788)
- Testing
- PH94B intranasal spray
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Depression, Anxiety Disorders
Prospective Study of the Evaluation of Disease contRol and the Quality of Life of Patients With depressiOn and With or Without aNxiety disOrders in the Greek populatIon
Depression is a psychiatric disorder that affects mood, thoughts and is usually accompanied by physical annoyances. It affects the person's eating habits, his sleep, the way he sees himself and the way he thinks and understands.
- Trial name
- PRONOI (NCT03317262)
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Generalized Anxiety Disorder
Echinacea Angustifolia (AnxioCalm) in Anxiety
This study evaluates whether Echinacea angustifolia (AnxioCalm) is a safe and effective treatment for mild to moderate Generalized Anxiety Disorder (GAD) symptoms.
- Trial name
- NCT03463018
- Testing
- Echinacea angustifolia
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- EuroPharma, Inc.
Generalized Anxiety Disorder
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder
The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
- Trial name
- NCT00481325
- Testing
- pexacerfont, escitalopram
- Where
- 51 sites in United States
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Generalized Anxiety Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder…
- Trial name
- SILVER (NCT00322595)
- Testing
- Quetiapine fumarate, Paroxetine
- Where
- 86 sites in Argentina, Bulgaria and 13 more
- Volunteers
- 800 people
- Sponsor
- AstraZeneca